EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Efficacy and Safety of Juan Bi Pill with Add-on Methotrexate in Active Rheumatoid Arthritis: A 48-Week, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial

Qing-Yun Jia, Yi-Ru Wang, Da-Wei Sun, Jian-Chun Mao, Luan Xue, Xiao-Hua Gu, Xiang Yu, Xue-Mei Piao, Hao Xu, Qian-Qian Liang

Chinese Journal of Integrative Medicine · 2025

DOI: 10.1007/s11655-024-3768-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Chinese Journal of Integrative Medicine, 2025. Verfasst von Qing-Yun Jia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Spine Institute, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Methotrexate, Drugs, Chinese Herbal, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To explore the efficacy and safety of Juan Bi Pill (JBP) in treatment of active rheumatoid arthritis (RA). METHODS: From February 2017 to May 2018, 115 participants from 4 centers were randomly divided into JBP group (57 cases) and placebo group (58 cases) in a 1:1 ratio using a random number table method. Participants received a dose of JBP (4 g, twice a day, orally) combined with methotrexate (MTX, 10 mg per week) or placebo (4 g, twice a day, orally) combined with MTX for 12 weeks. Participants were required with follow-up visits at 24 and 48 weeks, attending 7 assessment visits. Participants were undergo disease activity assessment 7 times (at baseline and 2, 4, 8, 12, 24, 48 weeks) and safety assessments 6 times (at baseline and 4, 8, 12, 24, 48 weeks). The primary endpoint was 28-joint Disease Activity Score (DAS28-ESR and DAS28-CRP). The secondary endpoints included American College of Rheumatology (ACR) criteria for 20% and 50% improvement (ACR20/50), Health Assessment Questionnaire Disability Index (HAQ-DI), clinical disease activity index (CDAI), visual analog scale (VAS), Short Form-36 (SF-36) score, Medial Outcomes Study (MOS) sleep scale score, serum erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tender joint count, swollen joint count, and morning stiffness. The adverse reactions were observed during the treatment. RESULTS: After 12 weeks of treatment, DAS28-ESR and DAS28-CRP scores in both groups were lower than before treatment (both P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidMethotrexateDrugs, Chinese HerbalAntirheumatic AgentsHumansFemaleDouble-Blind MethodMaleMiddle AgedTreatment OutcomeDrug Therapy, CombinationAdultAged

Stichwörter der Autor:innen

Chinese medicineJuan Bi Pillactive rheumatoid arthritismethotrexaterandomized controlled trial

Substanzen

MethotrexateDrugs, Chinese HerbalAntirheumatic Agents

Autor:innen und Institutionen

  • Spine Institute, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
  • Spine Institute, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
  • Key Laboratory of Theory and Therapy of Muscles and Bones, Ministry of Education (Shanghai University of Traditional Chinese Medicine), Shanghai, 201203, China.
  • Department of Orthopedics, Linyi People's Hospital, Linyi, Shandong Province, 273000, China.
  • Department of Orthopedics, The Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
  • Department of Orthopedics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.

Zitieren

APA

Jia, Q. Y., Wang, Y. R., Sun, D. W., Mao, J. C., Xue, L., Gu, X. H., Yu, X., Piao, X. M., Xu, H., & Liang, Q. Q. (2025). Efficacy and Safety of Juan Bi Pill with Add-on Methotrexate in Active Rheumatoid Arthritis: A 48-Week, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-024-3768-7

Vancouver

Jia QY, Wang YR, Sun DW, Mao JC, Xue L, Gu XH, et al. Efficacy and Safety of Juan Bi Pill with Add-on Methotrexate in Active Rheumatoid Arthritis: A 48-Week, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Chinese Journal of Integrative Medicine. 2025. doi:10.1007/s11655-024-3768-7

BibTeX
@article{Jia2025,
  author = {Jia, Qing-Yun and Wang, Yi-Ru and Sun, Da-Wei and Mao, Jian-Chun and Xue, Luan and Gu, Xiao-Hua and Yu, Xiang and Piao, Xue-Mei and Xu, Hao and Liang, Qian-Qian},
  title = {Efficacy and Safety of Juan Bi Pill with Add-on Methotrexate in Active Rheumatoid Arthritis: A 48-Week, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Chinese Journal of Integrative Medicine},
  year = {2025},
  doi = {10.1007/s11655-024-3768-7}
}
Kostenlos starten →